Main > > >ALLERGY. *

Anaphylaxis. Emergency TREAT.: Epinephrine Injection, USP. (0.15 mg/0.30 mg Auto Injectors).
CA Launch Date: 2018. 09.07.
USA Approval Date: 2017. 11.20.
USA Launch Date: 2018. 05.01.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 01.25.




AntiHistaminics. Alcaftadine API
(*) Company; Patents & Web-Site Avai-
lable on Request.
UpDate: 2021. 01.25.




Asthma. TREAT.: OmalizuMAb for SubCu-
taneous Use.
Mechanism: Anti-IgE MAb
USA Approval >12 Years : 2003.
USA Approval 06-11 Years: 2016. 07.07.
(*) Companies; Patents; TradeMark &
Web-Site Available on Request.
UpDate: 2018. 04.01




Conjunctivitis. TREAT.: Cetirizine Solution 0.24%
USA Approval Date: 2017. 05.30.
USA Launch Date: 2020. 03.31.
(*) Company; Patent; TradeMark & Web-
Site Available on Request
UpDate: 2021. 01.25.




Conjunctivitis. TREAT.: Olopatadine.HCl
Solution 0.7% Solution
Sale Over-The-Counter (OTC)
USA Launch Date: 2020. 09.
USA Approval Date: 2020. 07.14.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 04.01.




Diagnostics. Testing Instrument.
USA Approval Date: 2018. 12.19.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 01.19.




Peanut Allergy. TREAT.: Peanut (Arachis hypogaea) Allergen Powder-dnfp Oral
ImmunoTherapy.
USA Approval Date: 2020. 01.31.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 03.31.




Rhinitis. TREAT.: Bilastine Tablet.
CA Launch Date: 2016. 12.19.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 04.01.













>ALLERGY. *'s products
This section has no products